The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells.

ABSTRACT: In this study we investigated the potential for the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) to modify energy metabolism in human primary skeletal muscle cells and mouse C2C12 skeletal muscle cells. The results showed that treatment of human myotubes with EMPA for 96 h decreased oxidation of exogenously added glucose and acetoacetate measured as CO₂ production, whereas CO₂ production from exogenously added fatty acids and leucine was increased compared to control cells. Uptake of acetoacetate by the cells was decreased by EMPA. Moreover, there were no EMPA-induced changes in glucose, fatty acid or leucine uptake by human myotubes, neither was lactate concentration in cell culture medium changed after exposure to EMPA. Treatment with EMPA i

SUBMITTER: Stevanovic S 

PROVIDER: S-EPMC12935846 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature